Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05386823 · ClinicalTrials.gov registry record · Phase 1
Evaluate the Safety, Tolerability and PK of HF1K16 in Healthy Volunteers
A Phase 1 study, sponsored by HighField Biopharmaceuticals Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT05386823 is a Phase 1 study that has completed, run by HighField Biopharmaceuticals Corporation. The registered enrollment target is 16 participants.
The verdict
NCT05386823, a Phase 1 study, has completed, sponsored by HighField Biopharmaceuticals Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
HF1K16 is an investigational pegylated liposome formulation of tretinoin for injection for the treatment of solid tumors through targeting myeloid derived suppressor cells (MDSCs). This phase 1 Trial is a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of HF1K16.
Interventions
- DRUG Placebo
- DRUG HF1K16
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2021-03-20 |
| Est. Completion | 2021-08-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05386823
The ClinicalTrials.gov registry entry for NCT05386823 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HighField Biopharmaceuticals Corporation, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05386823 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05386823 about?
NCT05386823 is a clinical study titled "Evaluate the Safety, Tolerability and PK of HF1K16 in Healthy Volunteers". HF1K16 is an investigational pegylated liposome formulation of tretinoin for injection for the treatment of solid tumors through targeting myeloid derived suppressor cells (MDSCs). This phase 1 Trial is a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Subjects to Evaluate the Safety, ...
What is the current status of trial NCT05386823?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2021-03-20. Estimated completion is 2021-08-04.
What interventions are being tested in trial NCT05386823?
The interventions under investigation include: Placebo (DRUG), HF1K16 (DRUG).
Who is sponsoring clinical trial NCT05386823?
This trial is sponsored by HighField Biopharmaceuticals Corporation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.